The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced o...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Clin Pharmacol
Main Authors: Bachmann, Hagen Sjard, Meier, Werner, du Bois, Andreas, Kimmig, Rainer, Kuhlmann, Jan Dominik, Siffert, Winfried, Sehouli, Jalid, Wollschlaeger, Kerstin, Huober, Jens, Hillemanns, Peter, Burges, Alexander, Schmalfeldt, Barbara, Aminossadati, Behnaz, Wimberger, Pauline
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Ltd 2015
Fag:
Pharmacogenetics
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631186/
https://ncbi.nlm.nih.gov/pubmed/26033044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12688
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker